{"schema_version":"secwatch.filing_event.v1","accession":"0000885725-24-000075","form_type":"8-K","ticker":"BSX","cik":"0000885725","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.264926+00:00","generated_at":"2026-05-30T04:10:34.824600+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Boston Scientific resumes AVANT GUARD trial in drug-naïve persistent AFib patients","bullets":["AVANT GUARD trial resumed after assessment of observations and DMC input.","Study targets new population of drug-naïve patients with persistent atrial fibrillation.","No financial impact or patient enrollment numbers disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0000885725-24-000075","json":"https://secwatch.observer/filing/0000885725-24-000075.json","markdown":"https://secwatch.observer/filing/0000885725-24-000075.md","text":"https://secwatch.observer/filing/0000885725-24-000075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000075/0000885725-24-000075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000075/bsx-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:10:34.824600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}